Form 4: Procept BioRobotics EVP, CFO Kevin Waters Reports Changes in Beneficial Ownership

Kevin Waters, EVP and CFO of Procept BioRobotics, reports acquisition of restricted stock units and stock options.

Summary

• Kevin Waters, the EVP and CFO of Procept BioRobotics Corp, filed a Form 4 with the SEC.
• The filing reports the acquisition of 16,290 shares of common stock in the form of restricted stock units (RSUs) and 14,388 stock options on March 3, 2025.
• The RSUs vest in installments starting March 5, 2026, with one-quarter vesting initially and the remainder vesting quarterly over 36 months, contingent upon continued service.
• The stock options vest monthly from March 5, 2025, over a four-year period, also subject to continued employment.
• Following these transactions, Waters beneficially owns 112,386 shares of common stock and 14,388 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the company's future, but doesn't contain overtly positive or negative information.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance by a key executive.

Risks

• The vesting of RSUs and stock options is contingent upon continued service, which introduces a risk of forfeiture if Waters leaves the company.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the RSUs and stock options imply a multi-year commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor management's alignment with shareholder interests.

Stakeholder Impact

• The vesting of equity to a key executive aligns their interests with those of shareholders, incentivizing them to drive long-term value creation.

Key Dates